MG Matt Gline Biotech industry voice who hosts Off-Target Effects with Matt Gline, a BiotechTV interview series with investors and company leaders such as Perceptive's Joe Ed...

“What you can read in the Isomorphic valuation is a bet by tech people that Isomorphic is going to be among the winners in AI for biotech. But at some point these markets are going to come crashing into one another, and we're going to have to figure out how AI for biotech gets valued when the thing it's valued on is actual drugs produced and marketed to the world.”

Biotech Hangout · Health & Longevity · November 2026

“What you can read in the Isomorphic valuation is a bet by tech people that Isomorphic is going to be among the winners in AI for biotech. But at some point these markets are going to come crashing into one another, and we're going to have to figure out how AI for biotech gets valued when the thing it's valued on is actual drugs produced and marketed to the world.” — Matt Gline, Biotech Hangout

Context

The hosts discussed Isomorphic Labs' reported raise at a $50 billion valuation, which people had compared with established drugmakers. Gline says tech investors and biotech investors value companies on completely different bases, and that the two will eventually have to reconcile.

Transcript

Biotech Hangout Around 42:12 into the episode
Matt Gline

…me is like an oversimple characterization, but I just feel like being afraid of new people coming in and developing drugs faster and better. Like that's just that to me shouldn't be the tone of the industry. I guess this to me is a little bit what Bruce and Peter both, I think, have advocated for.

Graig Suvannavejh

…earlier deals in pharma. They're not afraid to go early, pull it inside. It's not a China AI versus biotech. It's a pharma versus U.S. biotech. And so that's what I'm interested to watch. I am more in the camp of free markets. It's better for us. That's the thing that I think we need to keep. Well,

Matt Gline

pharma historically has. Anyway, we'll see how pharma does with early stage drug development as time goes on. Isomorphic raised, I think, $5 billion at a $50 billion valuation. And, you know, I think isomorphic has been around a little bit, but this is obviously just an incredibly eye-popping number. And there have been a bunch of people who have like tried in various ways to create, you know, valuation comparisons to like show other whatever. You know, UCB is a 50 billion dollar Euro market cap or, you know, Reuvin's a $28 billion market company. Biogen is a $37 billion market company. You look at isomorphic and you're like, that's a big number. And it is a big number. My only, like, the thing that I think is interesting about this is I think that desire to compare as between isomorphic's valuation and biotech companies valuations, I think, like misses an important point, which is that they are just trading on completely separate and largely disjointed markets. And so like the people involved in the isomorphic financing, you know, it was led by, I think, Green Oaks and Sequoia with, you know, with people like A16Z, who obviously do some biotech…

Graig Suvannavejh

I think that's a very fair point, Matt. There's a lot of other stuff that

Matt Gline

goes on in terms of valuations that is not so visible. Yeah. But there was quite recently one of these companies in the bioelectronics space. So, you know, the best known company is Elon Musk's company, Neuralink. I don't know what the valuation is on Neuralink, but a kind of related company that's…

Tim Opler

billion dollars at $45 billion pre. So that's, you know, isomorphic's valuation is not crazy at all. I do think that the tech bio space is starting to see a lot more action. I do think that Anthropic has highlighted the potential. And I personally think that, you know, our industry might look a…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.

More from Biotech Hangout